Relief Therapeutics Holding SA (OTCMKTS:RLFTF – Get Free Report) was the target of a large decrease in short interest in July. As of July 15th, there was short interest totaling 31,784 shares, a decrease of 61.2% from the June 30th total of 81,924 shares. Based on an average daily trading volume, of 9,525 shares, the short-interest ratio is presently 3.3 days.
Relief Therapeutics Stock Performance
Shares of Relief Therapeutics stock opened at $0.20 on Monday. The stock’s 50-day simple moving average is $0.35 and its 200-day simple moving average is $0.73. Relief Therapeutics has a 52 week low of $0.16 and a 52 week high of $4.88.
About Relief Therapeutics
Relief Therapeutics AG is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.
The company’s lead product candidate, RLF‐100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.
See Also
- Five stocks we like better than Relief Therapeutics
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for Relief Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relief Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
